Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

660
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
660
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.4K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.4K
Lipid Absorption01:24

Lipid Absorption

3.7K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.7K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

314
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
314
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

923
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
923

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decreased bone mineral density in adults with type 2 intestinal failure: A descriptive cross-sectional study.

JPEN. Journal of parenteral and enteral nutrition·2026
Same author

Incorporating solitary supplementary prescribing practice into an Advanced Practitioner role: The experience of a dietetic-based Advanced Practitioner in intestinal failure.

Intestinal Failure (New York, N.Y.)·2026
Same author

Stevia Rebaudiosides Usage as a Sugar Reduction Tool: A Narrative Review of Their Metabolic, Gut Microbiome and Weight Management Effects in Human Clinical Studies.

Nutrients·2026
Same author

Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Metabolic complications of home parenteral nutrition and chronic intestinal failure and indications for intestinal transplantation.

Clinical nutrition ESPEN·2026
Same journal

Finerenone Exposure and Ischemic Stroke in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity Score-Matched Cohort Study.

Clinical medicine (London, England)·2026
Same journal

Prevalence and predictive factors of chronic kidney disease among individuals with cardiometabolic risk factors: A multicenter cross sectional study, North East Ethiopia.

Clinical medicine (London, England)·2026
Same journal

Authors' response to Dr Lucy Williams' letter to the Editor: 'Life expectancy of UK physicians in the early 21st century: An analysis of 1,000 fellows from the Royal College of Physicians' Munk's Roll'.

Clinical medicine (London, England)·2026
Same journal

Resident doctor workforce wellbeing worldwide: lessons between the United Kingdom and Australia.

Clinical medicine (London, England)·2026
Same journal

Premature ventricular complexes.

Clinical medicine (London, England)·2026
Same journal

Heart failure with preserved ejection fraction (HFpEF): diagnosis and management for the general physician.

Clinical medicine (London, England)·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.7K

Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy.

Oluwafikunayo Orekoya1, John McLaughlin2, Eugenia Leitao3

  • 1Royal Bolton Hospital, Bolton, UK fikki.orekoya@nhs.net.

Clinical Medicine (London, England)
|June 3, 2015
PubMed
Summary
This summary is machine-generated.

Bile acid malabsorption (BAM) affects over half of patients tested. Bile acid sequestrants are effective, with colesevelam showing better tolerance and efficacy than colestyramine, especially in treatment failures.

Keywords:
DiarrhoeaSeHCATbile acid malabsorptionbile acid sequestrantcolesevelamcolestyramine

More Related Videos

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

10.1K
Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor
09:21

Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor

Published on: January 4, 2016

10.5K

Related Experiment Videos

Last Updated: Apr 11, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

11.7K
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
06:55

Ileectomy-induced Bile Overaccumulation in Mouse Intestine

Published on: August 21, 2017

10.1K
Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor
09:21

Real Time Monitoring of Intracellular Bile Acid Dynamics Using a Genetically Encoded FRET-based Bile Acid Sensor

Published on: January 4, 2016

10.5K

Area of Science:

  • Gastroenterology
  • Clinical Medicine
  • Diagnostic Medicine

Background:

  • Bile acid malabsorption (BAM) is a recognized cause of chronic diarrhea, yet diagnostic and treatment approaches remain debated.
  • Recent guidelines emphasize the need for more research due to limited evidence.

Purpose of the Study:

  • To investigate BAM subtypes and severity.
  • To evaluate the efficacy and tolerance of bile acid sequestrants (BAS).
  • To determine the prevalence of abnormal colonic histology in BAM patients.

Main Methods:

  • Retrospective review of 264 selenium-75-labelled homocholic acid conjugated taurine (SeHCAT) test records.
  • Data collected included BAM subtype and severity, colonic histopathology, and response to BAS.
  • Patient outcomes with colestyramine and colesevelam were specifically analyzed.

Main Results:

  • 53% of patients tested had BAM; type-2 BAM was prevalent in 45% of those with irritable bowel syndrome.
  • Colonic histological abnormalities were not significantly different between patients with or without BAM.
  • 63% of BAM patients responded to BAS, with response decreasing with severity. Colesevelam was effective in 47% of colestyramine failures and better tolerated.

Conclusions:

  • BAM severity is a useful predictor of BAS response.
  • Colesevelam offers a better-tolerated and effective alternative to colestyramine, particularly for treatment failures.
  • Colonic histology is not relevant for BAM diagnosis or management, and colestyramine failure does not rule out BAM.